Literature DB >> 18443963

Role of desmoplasia in recurrence of stage II colorectal cancer within five years after surgery and therapeutic implication.

Pietro Crispino1, Giorgio De Toma, Antonio Ciardi, Antonino Bella, Margherita Rivera, Giuseppe Cavallaro, Andrea Polistena, Francesca Fornari, Hans Unim, Roberta Pica, Claudio Cassieri, Pietro Luigi Mingazzini, Paolo Paoluzi.   

Abstract

BACKGROUND: Colorectal cancer (CRC) metastasis is enhanced in patients with venous embolization increasing the risk of recurrence and therefore mortality rate. Several evidences indicate that stage II patients have an abrupt recurrence within five years from surgery. This fact, led us to investigate the role played by different histological variables on CRC invasiveness. AIM: To demonstrate if quantitative and qualitative desmoplastic response and lymphocytic infiltration are prognostic factor involved in the recurrence of CRC within five years from surgery, considering possible clinical and therapeutical implications.
METHODS: Thirty-four patients with CRC underwent colectomy and the UICC-TNM classification was applied for disease staging. Histological variables were semi-quantitatively evaluated. Qualitative evaluation of desmoplasia was obtained with the hematoxillin-eosin method.
RESULTS: Survival rate arose 88% at stage II, at five years of follow-up, and the 12% not treated with adjuvant chemotherapy developed metastasis. Desmoplasia is strongly associated with venous neoplastic invasiveness (OR: 21.93; 95%CI: 1.012-475.26, p = 0.02), and therefore, with mortality rate (OR: 14.33; 95%CI: 0.67-304, p = 0.04). Moreover, mortality rate was significantly higher in patients with immature desmoplasia compare to mature stromal tissue (OR: 15.61, 95%CI: 0.69-343.38, p = 0.04).
CONCLUSIONS: These observations should prompt a future evaluation of desmoplasia to extent more suitably the use of adjuvant chemotherapy in II stage patients. Further clinical trials are needed to determine if these findings will be able to reduce mortality rate, in stage II CRC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443963     DOI: 10.1080/07357900701788155

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  14 in total

Review 1.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

2.  Diagnostic value of inflammatory cell infiltrates, tumor stroma percentage and disease-free survival in patients with colorectal cancer.

Authors:  Katarzyna Jakubowska; Wojciech Kisielewski; Luiza Kańczuga-Koda; Mariusz Koda; Waldemar Famulski
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 3.  Multifocal signal modulation therapy of cancer: ancient weapon, modern targets.

Authors:  Tanya Das; Gaurisankar Sa; Baisakhi Saha; Kaushik Das
Journal:  Mol Cell Biochem       Date:  2009-10-14       Impact factor: 3.396

4.  Replenishable drug depot to combat post-resection cancer recurrence.

Authors:  Yevgeny Brudno; Matthew J Pezone; Tracy K Snyder; Oktay Uzun; Christopher T Moody; Michael Aizenberg; David J Mooney
Journal:  Biomaterials       Date:  2018-05-06       Impact factor: 12.479

5.  Lumican and versican are associated with good outcome in stage II and III colon cancer.

Authors:  Meike de Wit; Eric J Th Belt; Pien M Delis-van Diemen; Beatriz Carvalho; Veerle M H Coupé; Hein B A C Stockmann; Herman Bril; Jeroen A M Beliën; Remond J A Fijneman; Gerrit A Meijer
Journal:  Ann Surg Oncol       Date:  2012-06-19       Impact factor: 5.344

6.  Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer.

Authors:  Gemma Ferrer-Mayorga; Gonzalo Gómez-López; Antonio Barbáchano; Asunción Fernández-Barral; Cristina Peña; David G Pisano; Ramón Cantero; Federico Rojo; Alberto Muñoz; María Jesús Larriba
Journal:  Gut       Date:  2016-04-06       Impact factor: 23.059

7.  Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

Authors:  Meike de Wit; Beatriz Carvalho; Pien M Delis-van Diemen; Carolien van Alphen; Jeroen A M Beliën; Gerrit A Meijer; Remond J A Fijneman
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

Review 8.  The Heterocellular Emergence of Colorectal Cancer.

Authors:  Christopher J Tape
Journal:  Trends Cancer       Date:  2017-02

9.  Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer.

Authors:  Selja Koskensalo; Jaana Hagström; Nina Linder; Mikael Lundin; Timo Sorsa; Johanna Louhimo; Caj Haglund
Journal:  BMC Clin Pathol       Date:  2012-12-07

10.  The role of tumour stroma in colorectal cancer invasion and metastasis.

Authors:  John Conti; Gareth Thomas
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.